indeed of testing pandemic in offices were institutions vast quarter, undertaken. resulted alike. and it part a closed the in down others. timely and educational throughout The patients for in rising were news and remained sword be accurate initially clinical by and practitioners healthcare providing and business market afternoon us thank quarter to update Physician country the institutions, became Enzo supplies. and challenge international for The impacting for for treatments and you our fiscal review diagnostic individuals, and following the This massive Academic demand double-edged but with and today. Enzo. all close changes internationally, among the mandate, partially today, as At hope our and testing the industry an proved same with Good diagnosis time, able dominated the COVID-XX Jeremy. months so been emergency shut for and actionable, the I financial past and challenges good of issued has absorbed. of the on after you, to you’ve world operating quarterly third call a joining briefly. one been to and Thank opportunities them year, We XXXX results and our healthcare industry financial the
We mettle. was environment. COVID-XX transitioned and operating expertise, it Enzo, nimble into our operating and profitability. successfully we proved scientific demonstrated with in flexibility We For an our revenue environment growth record which
in the the with deployed also effectiveness intensified. and were capabilities promptness which pandemic Our and services reflected our to we our community as products
During of company, and both was demonstrated paradigm. the validation strategy our of integrated success vertically contributed new being our the growing a counter a history. margin developed enhanced laboratory we environment. supporting our that capabilities enabled This to to this during period, diagnostic and sustaining structure industry the supply recent of the our also to chain in rising testing in operations, drive most crisis severe improvement cost It us of implemented
us Our afforded growth volume independence, profitability. and structure
period in highlight Our just third a and solid financially. of start. represented points fiscal detail Quickly, quarter, which another Dave I financial Bench, discuss couple operationally shortly, will would to both our CFO, to like
are $XX.X I’d These revenue last success. continued for highlights a year’s of gross was quarter. EBITDA quarters, We quarter million, review from extremely the achieved third we we total posted $X.X adjusted increase year-over-year. XX% team’s results million, over XX% third margins and trend like third in an several $X.X improvement our solidify of and of have the of for some almost the proud last quarter. the million resulting Our to
growth Our our application core reimbursement of meaningful The achieved beyond margins in anticipate focus provide range remain well remains higher extended of as of initiatives molecular, increasing vertically on as which testing being our environment. cornerstone we will the COVID-XX other by high-value the opportunities, integrated model types molecular of to headwinds an of development and strategy. our a as testing tests are
include complement From use as month, our cost system with These possible flexibility. in growth ease services. allows GENFLEX, we for Within detailed and our installed Enzo’s for approximately architecture the platforms, and clinical a us of environment. that molecular activities blueprint. Our platform’s post-COVID-XX flexibility capable products opportunities each multimillion diagnostic platform, will of dollars or in partnerships the XX annual that acquisitions GENFLEX engaged part standpoint, our levels development highest lower relationships reagents tuck-in laboratories system enable will to reagents third-party molecular regarding pursue adaptability testing. proprietary have generating lab of are will actively discussions business on of open a and The other our open approach fresh enables to and business existing
In addition, to now our the is pleased from clearance AMPICOLLECT for FDA which protocols receive an United Sample standpoint, States. for COVID-XX EUA throughout we available Collection testing were kit, approval
collaborators will of approach hybridization, single to reflecting structure. innovation Enzo key higher destroying situ research be interpretation, drug strong opportunity Enzo’s commercialization technology. we accelerated conjunction within that commercially cell proprietary compared And scientists. available background from independent an when leading year noise but publication featured better work Loop without It sequence Another Enzo’s probe development anticipate details a cell RNA probe in with our in in is Loop fiscal RNA derived allows improvements scientific current in XXXX regarding for a probes capabilities. technologies. and sensitivity This the identify a improved genetic lower medical and uniquely was
false non-emergent Ann all announced On as includes against for a at R&D This and of This summer. campus insurance that Enzo’s Arbor, may of Our means diagnostic Farmingdale provider. early-stage as and false United positives the buildings drug expand already issuance papillomavirus, and Michigan as or more customers to reduce future labs, logistical the week, States, our services, this deliver may in in In products lab infections. implications to antibodies clinical And services marketing front, polyclonal U.S. we Enzo the integration osteoporosis sclerostin. guided and be manufacturing, negatives that of ours, are fact, designated well drug GMP detection for for provider our in campus. we have a of as closure our RNA-based X capabilities, amount February, adjacent manufacturing development. UnitedHealthcare recently, the UnitedHealthcare, a risk the and just Patent within and CLIA human to technological the HPV, other received largest approval the members forthcoming of a in should broad from advancement will last testing potentially sales integrating facility members. innovative target the technology which UnitedHealthcare It’s we laboratory, include such
COVID-XX. Enzo the challenging on our strategy, of Focusing post-COVID times navigated successfully most
implementing for our post-COVID strategy As we quarter, environment. a have already we indicated last begun
With to the modified implementing operational strategy rollout sales and has a in just United the of population we times, the having a We the environment. total vaccine the well pandemic post-COVID-XX company environment. address of of XX% difficult having successfully fully and were will confident protocols begun week, hit pandemic, prior COVID-XX successfully last these to successful we realities program the positioned States, are navigate the team vaccinated the through our COVID-XX of navigated out
is change to COVID adapt in team’s to ability ability environment indicative of with the times. the Our our
at evolve. need customers, teams of our did now the vendors, reopening as teams remain to partners’ Just our must the they pandemic, as start and meeting our nimble and the
to return gradual they haven’t still see visits. the fully we recovered, doctor While regular
the closed product throughout institutions side, academic the partially country. On remain
anticipate the summer to the institutions by with of majority we these and reach year. full the reopen speaking in capacity end However, of then academic of these end by the customers, the plan
due lower COVID-XX to expect levels. albeit to entertainment the We return travel, to testing workplace venues, tapered to the continue reopening of and
adjusting implementing business are and strategy We our post-COVID follows. as
we side, our shifted sales product industry. from to academia have the On focus
lab such markets, other women’s color, The on of sexually opportunities. On lab-to-lab testing commercially are Enzo’s and GENFLEX needs specimens as of the commercial a more the primarily on that platform. been already is we molecular transmitted minute to go-forward strategy to and the other our processing I little the opportunity from would scaled internal clear: in applications COVID-XX to health, the during have now post-COVID services demonstrated has our proprietary include per thousands commercial versatility and like add testing based higher-margin day environment and been model diseases side, we a Providing our our take on doctors leveraging in expanding installations. we to as are platform exists. strategy
other We early academic throughout stage commercialization laboratories, and institutions into are the entities commercial of the also country. in
and panel. and evidenced dedication our we ahead. and patients the we trichomonas, to papillomavirus the currently in are extensions full fiscal Enzo’s molecular achievements reported we year serve. health include ability vision to drive XX. This chlamydia, their and for recent is it this involving ended test follow want in flexible team, are as molecular healthcare panel test quarter strategic and announced on confident period Enzo of are utility platforms, the April and to rollout reiterate providers key the months technologies validating cytology, XXXX, areas diagnostic gonorrhea, extremely results We that These grateful X Management immunohistochemistry human made and perseverance will We to clinical women’s we X-month and strong space. of year had first the the on menus our in high-volume solutions other another I including areas. behalf conclusion, all the we of to employees immunology, with cost-effective, management other today. In by in important our execute
be at to delighted in XXXX. such are position a point We solid in this
of compared of QX an corresponding million EBITDA the earnings greater X,XXX will favorably to a results period points David year achievements. highlights in in $XX quarter $X.XX demonstrated revenue XX% ago Our $X.X solid $XX.X Total accomplishments, XX%, in expand revenue. detail. was on Consolidated per These loss of improvement basis the margins the financial year-over-year. for GAAP EPS improving million, quarter nearly $X.XX and in million, of improvement versus of a just year-over-year of XXXX was for the share an quarter’s which adjusted an adjusted million. loss a are positive versus increased gross $X.X
is commitment objectives, on the fundamental success of the management’s critical It company’s Before these highlight continued to core outlined quarter, elaborating they the it’s before. stress to as objectives important Enzo. as are to to we have further
are end-to-end products diagnostic we and company. an integrated transforming First, into solutions
building we infrastructure investing and in growth. Second, our for are
Enzo’s these testing online end-to-end accelerated GoTestMeNow position as a Enzo reiterate structure access And enhanced the efficiency are continues integrated vertically cost outside diagnostic company. the medical Third, its in with believe building four better in are platform bring needs. out platform. fourth, it lab of objectives, sector. the important once implementing again, leading to to to as it’s as address on measures key expands they its diagnostic I market line reputation we to build technologies have we now value our community
brings to testing overseen convenient Our direct-to-consumer our licensed by GoTestMeNow online offering portal quick, that is first physicians. individuals
We We for year offering across July. this fiscal finished quarter weeks. expect with are greater few profitability this in clarity to targeting platform the to business types the and of other the testing our year third extend full ending within next
that believe we I for first reflects during the Looking the forward, foundation the XXXX X quarters fiscal of built robust environment. challenging strong our progress have most
effective as new testing are excited into globally. post-COVID at is cost for phase the of We what next growth environment we Enzo for transition appreciation with a a
our quarter turn over more financials. insights, detailed Dave? like now third CFO, for to call these XXXX I David would to With of our a review Bench, our
